Report | China Deal Review Q4 2024 - Leaderboard

China's gene-editing startup Qihan Biotech raises $25.5m in Series A+ round

China's gene-editing startup Qihan Biotech raises $25.5m in Series A+ round

Chinese gene-editing technology developer Qihan Biotech announced on Monday that it has secured $25.5 million in a Series A+ funding round, bringing life-saving organ transplantation solutions to serve the largely untapped market in China.